☆ 4.1 Review

Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Related references

Note: Only part of the references are listed.

Review Endocrinology & Metabolism

Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta-analysis of randomized controlled trials

Y. Zhou et al.

Summary: The study indicates that endothelin receptor antagonists can significantly reduce albuminuria levels and have renal protective effects for patients with diabetic kidney disease. Atrasentan and avosentan are effective drug options, with the former showing the best renal protection effect at a daily dose of 0.75mg. Vigilant monitoring of congestive heart failure risk is necessary in future clinical practice.

DIABETIC MEDICINE (2021)

Add to Collection

Article Endocrinology & Metabolism

Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Jeroen Koomen et al.

Summary: The study found that atrasentan plasma exposure varies among individual patients and partially explains the differences in UACR and BNP response among patients. In addition, Caucasian patients showed better response in UACR reduction and BNP increase compared to black patients.

DIABETES OBESITY & METABOLISM (2021)

Add to Collection

Article Urology & Nephrology

New insights from SONAR indicate adding sodium glucose co-transporter 2 inhibitors to an endothelin receptor antagonist mitigates fluid retention and enhances albuminuria reduction

Hiddo J. L. Heerspink et al.

Summary: The study suggests that the combined use of SGLT2i and ERA drugs may be beneficial in patients with diabetes and chronic kidney disease, reducing body weight and decreasing albuminuria. This supports further clinical research into the long-term efficacy and safety of SGLT2i/ERA combination treatment.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Multidisciplinary Sciences

Diabetic kidney disease in type 2 diabetes: a review of pathogenic mechanisms, patient-related factors and therapeutic options

Louise Woodhams et al.

Summary: The global prevalence of diabetic kidney disease is increasing rapidly due to the rising number of individuals with type 2 diabetes. Over the past decade, there has been increased interest in understanding the pathogenic mechanisms and patient-related factors involved in the development and progression of this disease, which will influence the development of novel treatments and current clinical practices.

PEERJ (2021)

Add to Collection

Editorial Material Urology & Nephrology

SONAR: Do a New Design and Statistically Significant Results Translate to Reliability?

Michael Walsh

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)

Add to Collection

Review Endocrinology & Metabolism

Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review

Li Zhang et al.

WORLD JOURNAL OF DIABETES (2020)

Add to Collection

Article Medicine, General & Internal

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J. L. Heerspink et al.

LANCET (2019)

Add to Collection

Article Pharmacology & Pharmacy

Relationship Between Atrasentan Concentrations and Urinary Albumin to Creatinine Ratio in Western and Japanese Patients With Diabetic Nephropathy

Chih-Wei Lin et al.

CLINICAL THERAPEUTICS (2018)

Add to Collection

Article Endocrinology & Metabolism

Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight

Jeroen V. Koomen et al.

DIABETES OBESITY & METABOLISM (2018)

Add to Collection

Review Medicine, General & Internal

Diabetic nephropathy: newer therapeutic perspectives

Krishna C. Keri et al.

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES (2018)

Add to Collection

Article Pharmacology & Pharmacy

Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial

David J. Webb et al.

DRUGS IN R&D (2017)

Add to Collection

Article Urology & Nephrology

Diabetic Kidney Disease Challenges, Progress, and Possibilities

Radica Z. Alicic et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)

Add to Collection

Article Endocrinology & Metabolism

The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy

Michelle J. Pena et al.

DIABETES OBESITY & METABOLISM (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers

Bauke Schievink et al.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Relationship Between Dyslipidemia and Albuminuria in Hypertensive Adults A Nationwide Population-Based Study

Sung-Ho Lee et al.

MEDICINE (2016)

Add to Collection

Article Urology & Nephrology

Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy

Donald E. Kohan et al.

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)

Add to Collection

Article Urology & Nephrology

Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis

Wenming Yuan et al.

NEPHROLOGY (2015)

Add to Collection

Review Medicine, General & Internal

Endothelin Blockade in Diabetic Kidney Disease

Lidia Anguiano et al.

JOURNAL OF CLINICAL MEDICINE (2015)

Add to Collection

Editorial Material Urology & Nephrology

Endothelin Antagonists in Diabetic Nephropathy: Back to Basics

Kiran Chandrashekar et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)

Add to Collection

Article Urology & Nephrology

The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy

Dick de Zeeuw et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)

Add to Collection

Review Pharmacology & Pharmacy

Update on Potential Drugs for the Treatment of Diabetic Kidney Disease

Brian Shepler et al.

CLINICAL THERAPEUTICS (2012)

Add to Collection

Article Endocrinology & Metabolism

The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial

A. Rafnsson et al.

DIABETOLOGIA (2012)

Add to Collection

Article Medicine, Research & Experimental

Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)

Dennis L. Andress et al.

LIFE SCIENCES (2012)

Add to Collection

Article Urology & Nephrology

Addition of Atrasentan to Renin-Angiotensin System Blockade Reduces Albuminuria in Diabetic Nephropathy

Donald E. Kohan et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)

Add to Collection

Article Medicine, General & Internal

The Cochrane Collaboration's tool for assessing risk of bias in randomised trials

Julian P. T. Higgins et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Article Urology & Nephrology

Avosentan for Overt Diabetic Nephropathy

Johannes F. E. Mann et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)

Add to Collection

Article Urology & Nephrology

Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria

Rene R. Wenzel et al.

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.